Results 231 to 240 of about 115,960 (309)

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

Rod-Like Cytoplasmic Inclusions in the Peripheral Blood Smear of a Patient with Chronic Lymphocytic Leukemia. [PDF]

EJHaem
Prasad A, Nguyen TB, Carrillo LF.
europepmc   +1 more source

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: Results for CALGB 10404 (Alliance) [PDF]

Fehniger, Todd A.
core  

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance. [PDF]

Curr Hematol Malig Rep
Al-Abdulmalek A, Landry E, Abdulgayoom M, Al-Mashdali AF, Dalol AA, Muthanna B, Routy JP, Mohamed SF.   +7 more
europepmc   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

International Journal of Dermatology, EarlyView.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini, Carlo Alberto Maronese, Federica Derlino, Giovanni Genovese, Chiara Moltrasio, Luisa Sarno, Stefano Buffon, Bianca Cei, Giammarco Granieri, Valentina Dini, Marco Romanelli, Vincenzo Maione, Stefano Bighetti, Marina Venturini, Edoardo Cammarata, Paola Savoia, Antonio Di Guardo, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Lorenza Burzi, Claudia Leporati, Nunzia Di Cristo, Nicola Zerbinati, Alex G. Ortega‐Loayza, Angelo Valerio Marzano   +25 more
wiley   +1 more source

Adverse Effects of Low Serum HDL-C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. [PDF]

Cancer Med
Lv W, Liu S, Song J, Liang Z, Liao H, Huang Q, Zhu Z, Mo Z, Wang Y, Liang Y.   +9 more
europepmc   +1 more source

Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape. [PDF]

Hemasphere
Drewes C, López C, Martinez-Manjón JE, Okeke N, Jebaraj B, Bens S, Brändl B, Dyer MJS, Eichhorst B, Fischer A, Fischer K, Robrecht S, Hallek M, Glaser S, Hillebrecht S, Jayne S, Kretzmer H, Mottok A, Müller FJ, Schneider C, Ammerpohl O, Del Val C, Stilgenbauer S, Tausch E, Siebert R.   +24 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

Bartlett, Nancy L, et al.,
core  

Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Diagnostic and Therapeutic Challenge. [PDF]

EJHaem
Ye MT, Yang Y, You MJ.
europepmc   +1 more source